Virtual Meeting to be held on April 23 hosted by Lake Street. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.

SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

Cash, cash equivalents and marketable securities as of December 31, 2024 totaled $27.6M, compared to $48.5M for the year ended December 31, ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full ...

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.